CT/NG Testing Market Size & Growth Forecast 2027–2036, By Segments (Product Type, Test Type, Technology, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to content
Market Size and Growth Outlook
CT/NG Testing Market size was more than USD 1.79 Billion in 2026 and is set to grow at 7.53% CAGR between 2027 and 2036, exceeding USD 3.7 Billion by 2036. The industry revenue for 2027 is calculated at USD 1.9 Billion.
Get more details on this report
Request Free Sample ReportCT/NG Testing Market Intelligence Snapshot
Regional Market Dynamics
- North America held 38.45%, supported by advanced diagnostic infrastructure, broad molecular testing access, STI awareness, and public health screening initiatives.
- Asia Pacific is expected to grow fastest as healthcare expenditure, molecular testing availability, infectious disease screening, and diagnostic infrastructure expand.
Segment Momentum
- Consumables accounted for 71.9% of the market in 2026 because test kits, reagents, and assay materials are required for every diagnostic procedure, creating recurring demand across healthcare facilities and diagnostic laboratories.
- Point-of-care testing is growing the fastest as it enables rapid diagnosis, immediate clinical decisions, and improved patient access without relying on centralized laboratories, supported by advances in portable diagnostic technologies.
Market Expansion Drivers
- Increasing STI incidence driving demand for routine diagnostic CT/NG screening programs
- Expanding public health awareness and screening initiatives improving early infection detection rates
- Advancements in molecular diagnostics enabling faster and more accurate infectious disease testing
Leading Market Participants
- Leading players in the CT/NG testing market include Abbott Laboratories (United States), Becton, Dickinson and Company (United States), Cepheid (United States), Hologic, Inc. (United States), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Seegene, Inc. (South Korea), Thermo Fisher Scientific Inc. (United States), Bio-Rad Laboratories, Inc. (United States), Meridian Bioscience, Inc. (United States)
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 1.79 Billion
- 2027 Estimated Market Size: USD 1.9 Billion
- Projected Market Size: USD 3.7 Billion by 2036
- Growth Forecast: 7.53% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Consumables (Product Type) | Laboratory Testing (Test Type) | Polymerase Chain Reaction (Technology) | Hospitals & Clinics (End-use)
- Emerging Opportunity Segment: Instruments/Analyzers (Product Type) | Point-of-care (POC) Testing (Test Type) | Isothermal Nucleic Acid Amplification Technology (Technology) | Home Care Setting (End-use)
Market Growth Drivers and Industry Trends
Increasing STI incidence driving demand for routine diagnostic CT/NG screening programs
The growing incidence of sexually transmitted infections is prompting healthcare providers to strengthen routine screening practices and expand access to diagnostic services across diverse patient populations. This trend will drive the CT/NG testing market growth as clinicians increasingly emphasize early identification of chlamydia trachomatis and neisseria gonorrhoeae infections to reduce disease transmission and prevent long-term reproductive health complications. Routine screening in primary care settings, sexual health clinics, and prenatal care programs supports timely treatment decisions while improving surveillance efforts and enabling more effective management of asymptomatic infections.
Expanding public health awareness and screening initiatives improving early infection detection rates
Public health campaigns are increasing awareness of sexually transmitted infections by encouraging preventive healthcare, reducing stigma associated with testing, and promoting routine screening among at-risk individuals. The CT/NG testing market benefits from broader screening initiatives that improve access to diagnostic services through community outreach programs, educational efforts, and integrated healthcare services. Earlier detection enables healthcare professionals to initiate prompt treatment, strengthen contact tracing activities, and reduce the likelihood of untreated infections contributing to wider community transmission.
Advancements in molecular diagnostics enabling faster and more accurate infectious disease testing
Continuous innovation in molecular diagnostic technologies is enhancing the speed, sensitivity, and reliability of infectious disease detection across clinical laboratories and point-of-care settings. These technological advances will propel the CT/NG testing market growth by enabling highly accurate identification of pathogens from a wide range of specimen types while reducing turnaround times for diagnostic results. Improved automation, streamlined laboratory workflows, and enhanced assay performance support efficient clinical decision-making and facilitate broader adoption of molecular testing in routine infectious disease management.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing STI incidence driving demand for routine diagnostic CT/NG screening programs | 2.3% | High | North America, Europe, Asia Pacific | High | Near Term |
| Expanding public health awareness and screening initiatives improving early infection detection rates | 2.1% | High | North America, Europe | High | Near Term |
| Advancements in molecular diagnostics enabling faster and more accurate infectious disease testing | 1.9% | High | North America, Asia Pacific | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America held the largest share of 38.45% of the CT/NG testing market in 2026, supported by advanced diagnostic infrastructure, strong awareness of sexually transmitted infections, and broad access to laboratory and molecular testing services. Increasing emphasis on early detection and treatment of sexually transmitted infections is encouraging the utilization of accurate diagnostic methods for chlamydia and gonorrhea. The region's established healthcare systems and growing adoption of molecular diagnostic technologies are further supporting market development. In addition, public health initiatives focused on infection screening, prevention, and improved disease surveillance are strengthening demand for reliable CT/NG testing solutions.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is anticipated to be the fastest-growing regional market as awareness of sexually transmitted infections improves and diagnostic capabilities continue to expand. Rising healthcare expenditure, increasing availability of molecular testing, and efforts to strengthen infectious disease screening are encouraging greater access to CT/NG diagnostics. Expanding healthcare infrastructure in emerging economies is also helping extend testing services beyond major urban centers. Furthermore, growing public health attention toward sexually transmitted infections and increasing adoption of advanced laboratory technologies are expected to support wider testing and earlier identification of infections across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
United States 🇺🇸
Expanded Screening ProgramsThe U.S. market is characterized by broader screening initiatives and increasing use of molecular diagnostics for sexually transmitted infections. Healthcare providers in the U.S. are expanding access to rapid and laboratory-based CT/NG testing across public health and clinical settings.
Germany 🇩🇪
Laboratory Diagnostic IntegrationGermany is integrating CT/NG testing into established laboratory networks with a strong emphasis on diagnostic accuracy and standardized workflows. Demand in Germany is increasing for molecular testing platforms that support efficient screening and confirmatory procedures.
Japan 🇯🇵
Preventive Health MonitoringJapan is gradually increasing the use of CT/NG testing as preventive healthcare initiatives encourage earlier detection of sexually transmitted infections. Healthcare providers in Japan are adopting testing solutions that deliver reliable results with minimal operational complexity.
South Korea 🇰🇷
Rapid Testing AdoptionSouth Korea is expanding the use of rapid and molecular CT/NG diagnostic solutions in response to growing awareness of sexual health management. The country's healthcare providers are emphasizing accessible testing pathways and improved turnaround times.
France 🇫🇷
Public Health Surveillance SupportFrance utilizes CT/NG testing as part of broader public health strategies aimed at improving sexually transmitted infection monitoring. Diagnostic providers in France are prioritizing testing platforms that facilitate wider screening coverage and support preventive care initiatives.
Italy 🇮🇹
Community Testing ExpansionItaly is strengthening access to CT/NG testing through community healthcare networks and expanded diagnostic services. Laboratories and clinics in Italy are seeking cost-effective molecular testing solutions that improve detection rates and streamline patient management.
CT/NG Testing Market Share (%), by Product Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Type Segment Analysis: Consumables (Largest Segment) vs Instruments/Analyzers (Fastest-Growing Segment)
The consumables product type segment dominated the CT/NG testing market, accounting for 71.9% in 2026. Its leading position is primarily attributed to the recurring use of test kits, reagents, assay components, and other disposable materials required for routine sexually transmitted infection screening and diagnosis. The increasing volume of diagnostic testing, coupled with the need for consistent testing accuracy and uninterrupted laboratory operations, continues to generate sustained demand for consumables. Their essential role in every testing procedure ensures repeated purchasing across healthcare facilities and diagnostic laboratories.
The instruments/analyzers product type segment is expected to witness the fastest growth as healthcare providers increasingly invest in automated diagnostic platforms that improve testing efficiency, reduce turnaround times, and support higher sample throughput. Technological advancements in molecular diagnostics and laboratory automation are encouraging the replacement of conventional systems with more advanced analyzers. Growing demand for rapid and reliable diagnostic capabilities is expected to further accelerate adoption within this segment.
Test Type Segment Analysis: Laboratory Testing (Largest Segment) vs Point-of-care (POC) Testing (Fastest-Growing Segment)
The laboratory testing segment held the largest share of the CT/NG testing market, accounting for 70.37% in 2026. Laboratory-based testing remains the preferred approach because it provides high diagnostic accuracy, comprehensive testing capabilities, and the capacity to process large sample volumes efficiently. Advanced laboratory infrastructure, skilled personnel, and the widespread use of molecular diagnostic technologies continue to support the dominant position of this segment. Healthcare providers also rely on laboratory testing to ensure reliable confirmation of infections and appropriate clinical decision-making.
The point-of-care (POC) testing segment is anticipated to record the fastest growth as healthcare systems increasingly emphasize rapid diagnosis, immediate clinical decisions, and improved patient accessibility. Point-of-care testing enables healthcare professionals to deliver results quickly without depending on centralized laboratory infrastructure, supporting timely treatment and reducing follow-up delays. Rising demand for decentralized healthcare services and advancements in portable diagnostic technologies continue to drive the expansion of this segment.
Technology Segment Analysis: Polymerase Chain Reaction (Largest Segment) vs Isothermal Nucleic Acid Amplification Technology (Fastest-Growing Segment)
The polymerase chain reaction technology segment dominated the CT/NG testing market, accounting for 49.18% in 2026. Its leadership is supported by its high analytical sensitivity, strong specificity, and ability to accurately detect low concentrations of infectious genetic material. Polymerase chain reaction technology has become a widely adopted diagnostic method due to its reliability, standardized laboratory implementation, and compatibility with high-throughput testing platforms. Continued adoption of molecular diagnostics further reinforces the segment's dominant position.
The isothermal nucleic acid amplification technology segment is expected to witness the fastest growth as healthcare providers seek rapid molecular diagnostic methods that require simpler workflows and faster result generation. The technology enables efficient nucleic acid amplification without complex thermal cycling, making it particularly suitable for decentralized and point-of-care testing environments. Ongoing innovation in rapid diagnostic platforms and increasing demand for accessible molecular testing solutions are expected to support the continued growth of this segment.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product Type | Consumables, Instruments/Analyzers | Consumables | Instruments/Analyzers |
| Test Type | Laboratory Testing, Point-of-care (POC) Testing | Laboratory Testing | Point-of-care (POC) Testing |
| Technology | Isothermal Nucleic Acid Amplification Technology, Polymerase Chain Reaction, Immunodiagnostics, Others | Polymerase Chain Reaction | Isothermal Nucleic Acid Amplification Technology |
| End-use | Hospitals & Clinics, Diagnostic Laboratories, Home Care Setting, Others | Hospitals & Clinics | Home Care Setting |
Competitive Landscape and Market Positioning
Major players in the CT/NG testing market:
- Abbott Laboratories (United States)
- Becton Dickinson and Company (United States)
- Cepheid (United States)
- Hologic, Inc. (United States)
- Qiagen N.V. (Netherlands)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Seegene, Inc. (South Korea)
- Thermo Fisher Scientific, Inc. (United States)
- Bio-Rad Laboratories, Inc. (United States)
- Meridian Bioscience, Inc. (United States)
Diagnostic accuracy is becoming only one dimension of competition in the CT/NG testing market, as laboratories and test developers increasingly differentiate through workflow efficiency, faster result delivery, and broader integration with modern healthcare systems. Competitive positioning is shifting toward platforms that support decentralized testing environments while maintaining consistent analytical performance across diverse clinical settings. At the same time, growing emphasis on preventive healthcare and routine screening is encouraging suppliers to refine ease of use, automation, and interoperability, creating a market where operational efficiency and clinical accessibility are emerging alongside test performance as key sources of competitive advantage.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories (United States) | |||||||
| Becton Dickinson and Company (United States) | |||||||
| Cepheid (United States) | |||||||
| Hologic Inc. (United States) | |||||||
| Qiagen N.V. (Netherlands) | |||||||
| F. Hoffmann-La Roche Ltd. (Switzerland) | |||||||
| Seegene Inc. (South Korea) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Bio-Rad Laboratories Inc. (United States) | |||||||
| Meridian Bioscience Inc. (United States) |
Industry Development / News
| Company Name | Date | Key Development |
|---|---|---|
| Qiagen | Jan-24 | Qiagen received U.S. FDA clearance for the NeuMoDx CT/NG Assay 2.0, broadening the test menu for its automated NeuMoDx 96 and 288 clinical molecular testing platforms. This commercial clearance enables the direct detection of Chlamydia trachomatis and Neisseria gonorrhoeae in both symptomatic and asymptomatic patients, reinforcing the company's competitive positioning and revenue generation within the molecular assay market. |
| Abbott | May-22 | Abbott secured FDA clearance for its Alinity m STI Assay, a multiplex molecular test designed to simultaneously detect and differentiate Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium. This regulatory approval expands the company's diagnostic capabilities within the infectious disease testing sector, supporting broader customer acquisition and commercial penetration in clinical molecular diagnostics. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
CT/NG Testing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Sample Type | Urine Samples, Vaginal & Endocervical Swabs, Urethral & Penile Swabs, Pharyngeal & Rectal Swabs |
| Procurement Model | Direct Institutional Procurement, Group Purchasing Organization Procurement, Distributor-Mediated Procurement, Public & Government Procurement |
| Care Pathway | Routine Screening, Symptomatic Diagnosis, Prenatal & Antenatal Testing, Partner & Contact Testing, Test-of-Cure & Follow-Up |
CT/NG Testing Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Sexual Health Screening Program Assessment |
|
| Point-of-Care Testing Adoption Outlook |
|
| Self-Testing Market Opportunity Evaluation |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
How much revenue does the CT/NG testing market generate?
What is the projected value of the CT/NG testing industry by 2036?
How are routine screening programs influencing demand in the CT/NG testing market?
Why are molecular diagnostics becoming a strategic investment area in the CT/NG testing market?
Why do consumables hold the largest share in the CT/NG testing market?
Why is point-of-care (POC) testing the fastest-growing test type?
Why did North America hold 38.45% of the CT/NG testing market in 2026?
What is driving faster CT/NG testing growth in Asia Pacific?
What are the prominent companies operating in the CT/NG testing landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook